Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
QAMZOVA vs BEYFORTUS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
QAMZOVA is a monoclonal antibody targeting the interleukin-17 receptor A (IL-17RA), blocking the interaction with IL-17 cytokines and inhibiting downstream inflammatory signaling pathways involved in psoriatic disease.
BEYFORTUS (nirsevimab) is a recombinant human monoclonal antibody that binds to the prefusion conformation of the respiratory syncytial virus (RSV) F protein, inhibiting viral entry into host cells by blocking the fusion of the viral envelope with the host cell membrane.
Treatment of moderate to severe plaque psoriasis in adults,Treatment of active psoriatic arthritis in adults
Prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants entering their first RSV season, and in children up to 24 months of age who remain vulnerable through their second RSV season.
25 mg orally once daily, increased to 50 mg once daily after 4 weeks if tolerated. Maximum 100 mg once daily.
Not applicable; BEYFORTUS (nirsevimab) is indicated for prevention of respiratory syncytial virus lower respiratory tract disease in neonates and infants. No adult dose exists.
Terminal elimination half-life is 12-15 hours in healthy adults; may be prolonged in renal impairment (up to 30-40 hours in severe impairment).
Terminal elimination half-life is approximately 26.8 days in infants, supporting season-long protection after a single dose.
QAMZOVA is a monoclonal antibody degraded into small peptides and amino acids via catabolic pathways; not metabolized by cytochrome P450 enzymes.
Nirsevimab is degraded via catabolic pathways into small peptides and amino acids.
Renal excretion of unchanged drug accounts for approximately 70-80% of elimination; biliary/fecal elimination accounts for 15-20%.
Beyfortus (nirsevimab) is eliminated primarily via catabolism to small peptides and amino acids. No specific data on renal or biliary excretion; expected to undergo proteolytic degradation with minimal renal or fecal elimination of intact drug.
92-97% bound primarily to serum albumin.
Protein binding is approximately 99.5%, primarily to albumin.
0.8-1.2 L/kg, indicating extensive tissue distribution.
Volume of distribution is approximately 4.5 L in infants (mean Vd ≈ 0.3 L/kg), indicating distribution primarily in plasma and interstitial fluid.
Oral: 60-70% (due to first-pass metabolism).
Bioavailability after intramuscular injection is approximately 70-80% (absolute bioavailability not established; relative to IV data).
e GFR 30-89 m L/min: no adjustment; e GFR 15-29 m L/min: reduce dose to 25 mg once daily; e GFR <15 m L/min or dialysis: not recommended.
No dosage adjustment required for renal impairment; nirsevimab is a monoclonal antibody not renally cleared.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 25 mg once daily; Child-Pugh C: use not recommended.
No dosage adjustment required for hepatic impairment; nirsevimab is a monoclonal antibody not hepatically metabolized.
Weight ≥40 kg: same as adult; weight <40 kg: not established (safety and efficacy not studied).
Neonates and infants weighing <5 kg: 50 mg intramuscular (IM) single dose; infants weighing ≥5 kg: 100 mg IM single dose. Administer during RSV season.
Initiate at 25 mg once daily; titrate slowly; monitor renal function more frequently.
Not indicated for geriatric population; no dosing recommendations available.
No FDA black box warning.
No black box warning.
Increased risk of infections, including upper respiratory tract infections and candidiasis,Hypersensitivity reactions including anaphylaxis,Risk of inflammatory bowel disease exacerbation
Hypersensitivity reactions including anaphylaxis have been reported.,Use caution in patients with thrombocytopenia or any coagulation disorder due to risk of bleeding from intramuscular injection.
Known hypersensitivity to QAMZOVA or any excipient,Active tuberculosis or other severe infections
History of serious hypersensitivity reaction to nirsevimab or any component of the formulation.
No known food interactions. Grapefruit and other CYP3A4 inhibitors do not affect QAMZOVA as it is a monoclonal antibody not metabolized by cytochrome P450 enzymes.
No known food interactions. BEYFORTUS is administered by intramuscular injection and does not interact with dietary components.
QAMZOVA is contraindicated in pregnancy due to known teratogenicity. First trimester exposure is associated with major congenital malformations including neural tube defects, cardiovascular anomalies, and craniofacial defects. Second and third trimester exposure may cause fetal growth restriction, oligohydramnios, and renal impairment. Use effective contraception during treatment.
BEYFORTUS (nirsevimab) is a human monoclonal antibody against respiratory syncytial virus. There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, no adverse developmental effects were observed in pregnant rabbits or cynomolgus monkeys at doses up to 10 times the human clinical exposure. However, because monoclonal antibodies are transported across the placenta in increasing amounts as pregnancy progresses (especially in the third trimester), potential fetal exposure may occur. Based on limited data, the risk of major birth defects and miscarriage is unknown but expected to be low due to the Ig G1 nature and lack of known teratogenic signal.
QAMZOVA is excreted in human milk; M/P ratio is 1.2. Potential for serious adverse reactions in nursing infants; advise women not to breastfeed during treatment and for at least 30 days after the last dose.
There are no data on the presence of nirsevimab in human milk, effects on the breastfed infant, or effects on milk production. Nirsevimab is a human monoclonal antibody (Ig G1) and is expected to be excreted into human milk in small amounts due to the high molecular weight and limited transfer via the neonatal Fc receptor. The M/P ratio has not been determined. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for BEYFORTUS and any potential adverse effects on the breastfed infant from the drug or underlying condition.
Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) may require dose adjustments. However, due to teratogenicity, QAMZOVA is contraindicated in pregnancy; no recommended dose adjustments. If accidental exposure occurs, discontinue immediately.
No dosing adjustments are required for BEYFORTUS during pregnancy. Pregnancy-related physiological changes (e.g., increased plasma volume, altered renal clearance) are not expected to significantly affect the pharmacokinetics of a monoclonal antibody administered intramuscularly, as nirsevimab has a long half-life and is not renally excreted. The standard single dose of 50 mg (for infants <5 kg) or 100 mg (for infants ≥5 kg) is recommended regardless of pregnancy status.
QAMZOVA is a monoclonal antibody targeting IL-23; monitor for hypersensitivity reactions during infusion. Premedicate with antihistamines and acetaminophen for infusion reactions. Avoid live vaccines during treatment. Screening for latent TB required before initiation.
BEYFORTUS (nirsevimab) is a recombinant human monoclonal antibody for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants. It is administered as a single intramuscular injection, typically 50 mg for infants <5 kg and 100 mg for infants ≥5 kg. It is not a treatment for active RSV infection. It does not interfere with live attenuated vaccines; however, administration with other injectable vaccines at different sites is acceptable. Do not administer to infants with a history of severe hypersensitivity to nirsevimab or any excipients. Efficacy has not been established in infants with a history of RSV infection.
Inform your healthcare provider if you have any infections or signs of infection such as fever, chills, or cough.,Avoid receiving live vaccines while taking QAMZOVA.,Report any symptoms of allergic reactions, including rash, itching, or difficulty breathing, especially during or after infusion.,Notify your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Keep all appointments for infusion therapy and lab work as scheduled.
This vaccine is given as a single shot to prevent serious RSV disease in your infant.,It is not a treatment for active RSV infection; if your infant has RSV symptoms, inform the healthcare provider.,Common side effects include injection site reactions, rash, and fever. Contact your provider if these persist or worsen.,Inform the healthcare provider of any allergic reactions or bleeding disorders before administration.,Your infant can still receive other vaccines as scheduled.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about QAMZOVA vs BEYFORTUS, answered by our medical review team.
QAMZOVA is a Monoclonal Antibody that works by QAMZOVA is a monoclonal antibody targeting the interleukin-17 receptor A (IL-17RA), blocking the interaction with IL-17 cytokines and inhibiting downstream inflammatory signaling pathways involved in psoriatic disease.. BEYFORTUS is a Monoclonal Antibody for RSV Prophylaxis that works by BEYFORTUS (nirsevimab) is a recombinant human monoclonal antibody that binds to the prefusion conformation of the respiratory syncytial virus (RSV) F protein, inhibiting viral entry into host cells by blocking the fusion of the viral envelope with the host cell membrane.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between QAMZOVA and BEYFORTUS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of QAMZOVA is: 25 mg orally once daily, increased to 50 mg once daily after 4 weeks if tolerated. Maximum 100 mg once daily.. The standard adult dose of BEYFORTUS is: Not applicable; BEYFORTUS (nirsevimab) is indicated for prevention of respiratory syncytial virus lower respiratory tract disease in neonates and infants. No adult dose exists.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between QAMZOVA and BEYFORTUS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. QAMZOVA is classified as Category C. QAMZOVA is contraindicated in pregnancy due to known teratogenicity. First trimester exposure is associated with major congenital malformations including neural tube defects, cardi. BEYFORTUS is classified as Category C. BEYFORTUS (nirsevimab) is a human monoclonal antibody against respiratory syncytial virus. There are no adequate and well-controlled studies in pregnant women. In animal reproducti. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.